Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · February 17, 2022

Five-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC

Journal of Clinical Oncology


Additional Info

Journal of Clinical Oncology
Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
J. Clin. Oncol 2022 Feb 02;[EPub Ahead of Print], DR Spigel, C Faivre-Finn, JE Gray, D Vicente, D Planchard, L Paz-Ares, JF Vansteenkiste, MC Garassino, R Hui, X Quantin, A Rimner, YL Wu, M Özgüroğlu, KH Lee, T Kato, M de Wit, T Kurata, M Reck, BC Cho, S Senan, J Naidoo, H Mann, M Newton, P Thiyagarajah, SJ Antonia

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading